Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Insight Partners
Deal Size : $12.0 million
Deal Type : Financing
Details : The funding will be used in developing allogeneic NK cell-based immunotherapies for hematologic malignancies and solid tumors. NK cells represent a promising platform for allogeneic immunotherapy because they are potent cancer killers with a minimal risk...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Insight Partners
Deal Size : $12.0 million
Deal Type : Financing